Compare
Elanco Animal Health Inc vs Perrigo Co PLC vs Alnylam Pharmaceuticals, Inc. vs Organon & Co.
| Latest fiscal year | Elanco Animal Health Inc ELAN | Perrigo Co PLC PRGO | Alnylam Pharmaceuticals, Inc. ALNY | Organon & Co. OGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.71B | $4.25B | $3.71B | $6.22B |
| Revenue growth (YoY) | +6.2% | -2.8% | +65.2% | -2.9% |
| Gross margin | 55.0% | 35.1% | 81.8% (computed) | 53.3% |
| Operating margin | n/a | -26.4% | 13.5% | n/a |
| Net margin | -4.9% | -33.5% | 8.4% | 3.0% |
| Net income | -$232.00M | -$1.43B | $313.75M | $187.00M |
| EPS (Diluted) | -$0.47 | -$10.29 | $2.33 | $0.72 |
| Operating cash flow | $560.00M | $238.50M | $524.08M | $700.00M |
| Free cash flow | $284.00M | $145.10M | $465.38M | $538.00M |
| Cash & equivalents | $545.00M | n/a | $1.66B | $574.00M |
| Total assets | $13.36B | $8.54B | $4.97B | $12.87B |
| Total liabilities | $6.81B | $5.60B | $4.18B | $12.12B |
| Shareholders' equity | $6.55B | $2.94B | $789.18M | $752.00M |
| Return on year-end equity | -3.5% | -48.6% | 39.8% | 24.9% |
| Shares outstanding | 496.98M | 137.60M | 132.38M | 260.32M |
Revenue, most recent five fiscal years
| Fiscal year | Elanco Animal Health Inc | Perrigo Co PLC | Alnylam Pharmaceuticals, Inc. | Organon & Co. |
|---|---|---|---|---|
| Latest | $4.71B Ended 2025-12-31 | $4.25B Ended 2025-12-31 | $3.71B Ended 2025-12-31 | $6.22B Ended 2025-12-31 |
| 1 year earlier | $4.44B Ended 2024-12-31 | $4.37B Ended 2024-12-31 | $2.25B Ended 2024-12-31 | $6.40B Ended 2024-12-31 |
| 2 years earlier | $4.42B Ended 2023-12-31 | $4.66B Ended 2023-12-31 | $1.83B Ended 2023-12-31 | $6.26B Ended 2023-12-31 |
| 3 years earlier | $4.41B Ended 2022-12-31 | $4.45B Ended 2022-12-31 | $1.04B Ended 2022-12-31 | $6.17B Ended 2022-12-31 |
| 4 years earlier | $4.76B Ended 2021-12-31 | $4.14B Ended 2021-12-31 | $844.29M Ended 2021-12-31 | $6.30B Ended 2021-12-31 |